Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NOTA-RD06 is a radiopharmaceutical designed for Positron Emission Tomography (PET) imaging. It consists of the radioisotope Gallium-68 ([68Ga]), which is a positron emitter, chelated by 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). The 'RD06' component is presumed to be a targeting moiety, but its specific identity, biological target, and mechanism of action are not clearly defined or publicly documented in available scientific literature. Radiopharmaceuticals like this are generally used as diagnostic agents to visualize specific biological processes or disease markers in vivo. The Gallium-68 allows for detection via PET scanning, while the NOTA chelator stably binds the radioisotope to the targeting molecule. The specific function of the 'RD06' component would dictate the primary indication and the biological target of this particular radiopharmaceutical, but this information is currently unavailable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-NOTA-RD06.